Payment overview · 2025
General Payments
$670.09
21 reported records · 7 companies
Healthcare provider profile · identity verified
Patrick Melder, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ZEELAND, MI · NPI 1780688051
Verified facts
What the public records show
CMS Open Payments records show Patrick Melder, MD received $670.09 in general payments during 2025 across 21 reported records.
GENZYME CORPORATION accounted for 28.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trelegy Ellipta by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $192.84 | 28.8% | 7 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $141.76 | 21.2% | 1 | 2025 |
| AERIN MEDICAL INC. | Unresolved — no canonical attribution shown | $106.72 | 15.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $89.65 | 13.4% | 5 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $69.83 | 10.4% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $52.99 | 7.9% | 1 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $16.30 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $617.10 | 20 |
| Education | $52.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., SANOFI-AVENTIS U.S. LLC | $315.66 | 11 | 2025 |
Source payment records
|
|||||
| SCOPIS ENT Normalized: scopis ent |
Device | Stryker Corporation | $141.76 | 1 | 2025 |
Source payment records
|
|||||
| RHINAER STYLUS Normalized: rhinaer stylus |
Device | AERIN MEDICAL INC. | $106.72 | 3 | 2025 |
Source payment records
|
|||||
| VIVAER STYLUS Normalized: vivaer stylus |
Device | AERIN MEDICAL INC. | $106.72 | 3 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $89.65 | 5 | 2025 |
Source payment records
|
|||||
| ACCLARENT AERA Normalized: acclarent aera |
Device | Integra LifeSciences Corporation | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRA AIR Normalized: inspira air |
Device | Integra LifeSciences Corporation | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| RELIEVA SPINPLUS NAV Normalized: relieva spinplus nav |
Device | Integra LifeSciences Corporation | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| TruDi Probe Normalized: trudi probe |
Device | Integra LifeSciences Corporation | $16.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
83 | 78 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
64 | 13 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
87 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 855 | 99 |
| Furosemide | Furosemide | 849 | 124 |
| Atorvastatin Calcium | Atorvastatin Calcium | 687 | 154 |
| Eliquis | Apixaban | 636 | 84 |
| Sertraline Hcl | Sertraline Hcl | 526 | 96 |
| Potassium Chloride | Potassium Chloride | 525 | 118 |
| Gabapentin | Gabapentin | 510 | 98 |
| Mirtazapine | Mirtazapine | 280 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 272 | 61 |
| Losartan Potassium | Losartan Potassium | 271 | 46 |
| Lisinopril | Lisinopril | 263 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 258 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 243 | 72 |
| Trazodone Hcl | Trazodone Hcl | 227 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 218 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 211 | 35 |
| Donepezil Hcl | Donepezil Hcl | 206 | 37 |
| Quetiapine Fumarate | Quetiapine Fumarate | 198 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 196 | 35 |
| Divalproex Sodium | Divalproex Sodium | 195 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 193 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 182 | 41 |
| Famotidine | Famotidine | 179 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 175 | 28 |
| Prednisone | Prednisone | 175 | 86 |
| Olanzapine | Olanzapine | 171 | 29 |
| Memantine Hcl | Memantine Hcl | 168 | 24 |
| Jardiance | Empagliflozin | 164 | 21 |
| Carvedilol | Carvedilol | 162 | 35 |
| Risperidone | Risperidone | 156 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 153 | 63 |
| Cephalexin | Cephalexin | 146 | 74 |
| Levetiracetam | Levetiracetam | 139 | 29 |
| Metformin Hcl | Metformin Hcl | 134 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 129 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 129 | 37 |
| Tramadol Hcl | Tramadol Hcl | 126 | 22 |
| Xarelto | Rivaroxaban | 118 | 15 |
| Lorazepam | Lorazepam | 109 | 36 |
| Omeprazole | Omeprazole | 105 | 39 |
| Ipratropium Bromide | Ipratropium Bromide | 101 | 40 |
| Nystatin | Nystatin | 101 | 38 |
| Rexulti | Brexpiprazole | 93 | 14 |
| Lamotrigine | Lamotrigine | 91 | 11 |
| Simvastatin | Simvastatin | 90 | 20 |
| Bumetanide | Bumetanide | 89 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 18 |
| Montelukast Sodium | Montelukast Sodium | 89 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 88 | 19 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 87 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 85 | 57 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 83 | 78 |
| Ondansetron Hcl | Ondansetron Hcl | 83 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 83 | 30 |
| Oxybutynin Chloride | Oxybutynin Chloride | 81 | 19 |
| Baclofen | Baclofen | 78 | 19 |
| Torsemide | Torsemide | 78 | 25 |
| Farxiga | Dapagliflozin Propanediol | 73 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 73 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 45 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 70 | 25 |
| Spironolactone | Spironolactone | 70 | 22 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 69 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 66 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 64 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 64 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 13 |
| Aripiprazole | Aripiprazole | 61 | 15 |
| Alprazolam | Alprazolam | 60 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 57 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 57 | 20 |
| Novolog | Insulin Aspart | 56 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 56 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 14 |
| Finasteride | Finasteride | 55 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 13 |
| Trulicity | Dulaglutide | 54 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 52 | 13 |
| Buspirone Hcl | Buspirone Hcl | 52 | 17 |
| Lacosamide | Lacosamide | 52 | suppressed |
| Entresto | Sacubitril/Valsartan | 51 | suppressed |
| Latanoprost | Latanoprost | 51 | 13 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 50 | suppressed |
| Ezetimibe | Ezetimibe | 50 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 50 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 49 | 49 |
| Methylprednisolone | Methylprednisolone | 49 | 45 |
| Midodrine Hcl | Midodrine Hcl | 49 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 48 | 18 |
| Metformin Hcl Er | Metformin Hcl | 48 | 11 |
| Methocarbamol | Methocarbamol | 48 | 21 |
| Allopurinol | Allopurinol | 46 | 12 |
| Memantine Hcl Er | Memantine Hcl | 46 | suppressed |
| Lactulose | Lactulose | 44 | suppressed |
| Pregabalin | Pregabalin | 44 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 11 |
| Cefuroxime | Cefuroxime Axetil | 42 | 23 |
| Breyna | Budesonide/Formoterol Fumarate | 41 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Carbamazepine Er | Carbamazepine | 40 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Clonazepam | Clonazepam | 38 | 13 |
| Ibuprofen | Ibuprofen | 36 | suppressed |
| Ozempic | Semaglutide | 36 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 35 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 35 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 18 |
| Novolog Flexpen | Insulin Aspart | 35 | suppressed |
| Meloxicam | Meloxicam | 34 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 34 | suppressed |
| Carbamazepine | Carbamazepine | 33 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 31 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Movantik | Naloxegol Oxalate | 30 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Timolol Maleate | Timolol Maleate | 28 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 27 | suppressed |
| Fentanyl | Fentanyl | 27 | 11 |
| Gentamicin Sulfate | Gentamicin Sulfate | 27 | 23 |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 18 |
| Fluconazole | Fluconazole | 26 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 21 |
| Xifaxan | Rifaximin | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Briviact | Brivaracetam | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 23 | suppressed |
| Paricalcitol | Paricalcitol | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | 12 |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 21 | suppressed |
| Methadone Hcl | Methadone Hcl | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 21 |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 14 |
| Anastrozole | Anastrozole | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 20 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 20 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Klayesta | Nystatin | 19 | 12 |
| Tiotropium Bromide | Tiotropium Bromide | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 18 | suppressed |
| Insulin Lispro | Insulin Lispro | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 17 | 12 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Gvoke Hypopen 1-Pack | Glucagon | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Klor-Con 8 | Potassium Chloride | 16 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Galantamine Er | Galantamine Hbr | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Topiramate Er | Topiramate | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 13 | suppressed |
| Insulin Aspart | Insulin Aspart | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Glucagon Emergency Kit | Glucagon | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Betaseron | Interferon Beta-1b | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $670.09 · 21 records | GENZYME CORPORATION | ACCLARENT AERA, DUPIXENT, INSPIRA AIR, NUCALA, RELIEVA SPINPLUS NAV, RHINAER STYLUS, SCOPIS ENT, TruDi Probe, VIVAER STYLUS | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error